A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
- 试验地点
- 38
- 主要终点
- Dose Escalation Period: Number of participants with dose-limiting toxicities (DLTs)
研究概览
简要总结
DS-3201b is an experimental drug that is being investigated in clinical research.
Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to current treatment
This study has three parts. The Dose Escalation part is designed is to find the safe dose of DS-3201b that adults with advanced NHL can tolerate. The Dose Expansion phase will determine how effective DS-3201b is for rare types of NH and collect additional safety data. Last, the Drug-Drug Interaction (DDI) Cohort (US Only) will evaluate the effect of DS-3201b on the pharmacokinetics (PK) of midazolam and digoxin when co-administered to patients with NHL
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has hematocytological or pathological diagnosis of non- Hodgkin's lymphoma (NHL)
- •Has relapsed from or is refractory to standard treatment or no standard treatment is available
- •Is the age of majority in their country (18 in the US and 20 in Japan) at the time of informed consent
- •Has Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- •Has at least one evaluable lesion site (not applicable for the DDI cohort)
- •Has preserved organ function based on baseline laboratory data at screening tests
- •If of reproductive potential, agrees to avoid harvesting ova or sperm, and to use a protocol-defined form of contraception or avoid intercourse, during and upon completion of the study, and for at least 3 months after the last dose of study drug
- •Tumor biopsy collections:
- •willing to provide archived or fresh tumor tissue samples that are sufficient for comprehensive genomic and/or proteomic analyses at baseline
- •[US only] willing to provide fresh on-treatment tumor biopsy if deemed acceptable risk by the investigator
- •[Japan only] fresh on-treatment tumor biopsy should be performed if deemed acceptable risk by the investigator
- •willing to provide optional fresh end-of-treatment biopsy
- •For ATL subjects:
- •Has a positive test result for human T-lymphotropic virus type I antibody
- •Has ATL subtype classified as acute, lymphomatous, or chronic with poor prognostic factor
- •Has diagnosis of relapse (including relapse after partial remission [PR]) or treatment-resistant ATL at the time of informed consent after prior treatment with at least 1 anti-cancer medication regimen
排除标准
- •Has been diagnosed with protocol-defined cutaneous T-cell lymphoma or T-cell leukemia. For DDI cohort, CTCL is not exclusionary.
- •Has a history or presence of central nervous system (CNS) involvement
- •Has a medical history, complication or other malignancy considered inappropriate for participation in the study, or a serious physical or psychiatric disease, the risk of which may be increased by participation in the study
- •Has received drugs or other treatments not allowed by the protocol
- •History of treatment with other enhancer of zeste (EZH) inhibitors
- •Has had allogeneic hematopoietic stem cell transplantation (HTCP) within 90 days before scheduled dosing on Cycle 1 Day 1
- •Is pregnant or breastfeeding
- •Is otherwise deemed ineligible to participate by the investigator or sub-investigator
- •DDI Cohort Only:
- •Has received following medications within 14 days prior to study drug administration
- •Any CYP3A inhibitors/inducers including weak CYP3A inhibitors/inducers, and P-gp inhibitors, midazolam as well as digoxin
研究组 & 干预措施
Dose Escalation - DS-3201b
Dose escalation is to identify the recommended phase 2 dose of DS-3201b guided by the modified continuous reassessment method using a Bayesian logistic regression model following escalation.
干预措施: DS-3201b (Drug)
Dose Expansion - DS-3201b
Part 2 is a dose expansion to examine the safety and efficacy of DS-3201b.
干预措施: DS-3201b (Drug)
结局指标
主要结局
Dose Escalation Period: Number of participants with dose-limiting toxicities (DLTs)
时间窗: within 28 days after the initial dose of the study drug
Number of DLT-evaluable participants with protocol-defined DLTs
Dose Escalation Period: Maximum concentration (Cmax) of DS-3201
时间窗: within the first 28-day cycle
Categories: Cycle 1 Day 1, Cycle 1 Day 15
Dose Escalation Period: Time of maximum concentration (Tmax) of DS-3201
时间窗: within the first 28-day cycle
Categories: Cycle 1 Day 1, Cycle 1 Day 15
Dose Escalation Period: Area under the plasma concentration time curve up to the last quantifiable time (AUClast) for DS-3201
时间窗: Day 1 of the first 28-day cycle
Dose Escalation Period: Trough (minimum) plasma concentration (Ctrough)
时间窗: Day 15 of the first 28-day cycle
Dose Escalation Period: Average plasma concentration (Cavg)
时间窗: Day 15 of the first 28-day cycle
DDI cohort only: Area under the plasma concentration time curve up to the last quantifiable time (AUClast) for DS-3201,midazolam,digoxin
时间窗: within the first 28-day cycle
Categories: Day -4, Day 0 (for alternate schedule), Cycle 1 Day 1, Cycle 1 Day 15
Number of participants with treatment-emergent adverse events (TEAEs)
时间窗: through the end of the study (within approximately 5 years)
TEAEs are systematically collected from lab values, physical exams, and other investigations
Dose Escalation Period: Area under the plasma concentration time curve during the dosing interval (AUCtau) for DS-3201
时间窗: Day 1 of the first 28-day cycle
DDI cohort only: Maximum concentration (Cmax) of DS-3201, midazolam, digoxin
时间窗: within the first 28-day cycle
Categories: Day -4, Cycle 1 Day 1, Cycle 1 Day 15
DDI cohort only: Area under the plasma concentration time curve during the dosing interval (AUCtau) for DS-3201, midazolam, digoxin
时间窗: within the first 28-day cycle
Cycle 1 Day 1, Cycle 1 Day 15
DDI cohort only: Time of maximum concentration (Tmax) of DS-3201, midazolam, digoxin
时间窗: within the first 28-day cycle
Categories: Day -4, Day 0 (for alternate schedule), Cycle 1 Day 1, Cycle 1 Day 15
次要结局
- Best overall response, based on international consensus criteria(from the start of study treatment to the end of follow-up visit (within 5 years))
- Objective response rate (ORR)(within 5 years)
- Disease control rate (DCR)(within 5 years)
- Duration of response (DOR)(within 5 years)
- Progression-free survival (PFS)(witihn 5 years)
- Number of participants with malignant lymphoma who achieved each level of therapeutic response per international consensus standards(through the end of the study (within approximately 5 years))